2010 Fiscal Year Final Research Report
Development of new therapy for elder women with chronic hepatitis C
Project/Area Number |
20590474
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Virology
|
Research Institution | Okayama University |
Principal Investigator |
IKEDA Masanori Okayama University, 大学院・医歯薬学総合研究科, 准教授 (30315767)
|
Project Period (FY) |
2008 – 2010
|
Keywords | C型慢性肝炎 / HCV / ラロキシフェン / スタチン剤 |
Research Abstract |
Interferon and ribavirin therapy is a standard medication for chronic hepatitis C. However, the effect of the therapy is approximately 50%. The elder female patients are especially resistant to the therapy. To overcome this problem, we investigated the anti-hepatitis C virus (HCV) activity of osteoporosis reagent, raloxifene. Raloxifene exhibited anti-HCV activity by itself in cell culture system and enhanced anti-HCV activity of interferon. On the other hand, raloxifene reduced anti-HCV activity of cholesterol lowering reagent, statins.
|
-
-
-
-
-
-
[Journal Article] Oxidative stress induces anti-hepatitis C virus status via the activation of extracellular signal-regulated kinase.2009
Author(s)
Yano M, Ikeda M, Abe K, Kawai Y, Kuroki M, Mori K, Dansako H, Ariumi Y, Ohkoshi S, Aoyagi Y, Kato N.
-
Journal Title
Hepatology 20
Pages: 678-688
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Involvement of the MEK-ERK1/2 Signaling Pathway in the Anti-HCV Mechanism of Oxidative Stress.2009
Author(s)
Yano M, Ikeda M, Abe K, Kawai Y, Kuroki M, Mori K, Dansako H, Ariumi Y, Matsuda Y, Ohkoshi S, Aoyagi Y, Kato N
Organizer
The Liver Meeting 2009, AASLD
Place of Presentation
Boston, Massachusetts, USA
Year and Date
20091030-20091103
-
-
-
-
-
-
-
-
-
-